Incidence, Risk Factors and Surgical Outcomes of Cataract among Patients with Vogt-Koyanagi-Harada Disease

References

• Rao NA. Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye. 1997;11(Pt 2):213–216. doi:10.1038/eye.1997.54.
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606–614. doi:10.1016/j.ophtha.2006.07.040.
   PubMed Web of Science ®Google Scholar
• Fang W, Yang P. Vogt-Koyanagi-Harada syndrome. Curr Eye Res. 2008;33:517–523. doi:10.1080/02713680802233968.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91:e486–e493. doi:10.1111/aos.2013.91.issue-6.
   PubMed Web of Science ®Google Scholar
• Bacsal K, Wen DS, Chee SP. Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2008;145:480–486. doi:10.1016/j.ajo.2007.10.012.
   PubMed Web of Science ®Google Scholar
• Takemoto Y, Namba K, Mizuuchi K, et al. Choroidal circulation impairment during the anterior recurrence of Vogt-Koyanagi-Harada disease confirmed with indocyanine green angiography and laser speckle flowgraphy. Acta Ophthalmol. 2016;94:e629–e636. doi:10.1111/aos.13024.
   PubMed Web of Science ®Google Scholar
• Inomata H, Sakamoto T. Immunohistochemical studies of Vogt-Koyanagi-Harada disease with sunset sky fundus. Curr Eye Res. 1990;9:Suppl:35–40. doi:10.3109/02713689008999417.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP. Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2010;30:41–50. doi:10.1007/s10792-008-9288-1.
   PubMedGoogle Scholar
• Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2012;90:e603–e608. doi:10.1111/j.1755-3768.2012.02498.x.
   PubMed Web of Science ®Google Scholar
• Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt-Koyanagi-Harada’s disease. Jpn J Ophthalmol. 1988;32:334–343.
   PubMed Web of Science ®Google Scholar
• Read R, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001;131:599–606. doi:10.1016/s0002-9394(01)00937-0.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Mudhaiyan T, Al Najashi AA, et al. Chronic recurrent Vogt-Koyanagi-Harada disease and development of “sunset glow fundus” predict a worse retinal sensitivity. Ocul Immunol Inflamm. 2017;25:475–485. doi:10.3109/09273948.2016.1139730.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Dosari M, Hemachandran S, Gikandi PW, Al-Muammar A. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘sunset glow fundus ‘ in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2017;95:85–90. doi:10.1111/aos.13189.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Rajeev B, Smith RE, Rao NA. Incidence and management of cataracts in Vogte Koyanagie Harada syndrome. Am J Ophthalmol. 1994;118:197–204. doi:10.1016/s0002-9394(14)72899-5.
   PubMed Web of Science ®Google Scholar
• Tesavibul N, Sansanayuth W. Vogt-Koyanagi-Harada disease in Thai patients. J Med Assoc Thai. 2005;88:26–30.
   PubMedGoogle Scholar
• Yodmuang T, Rothova A, Kunavisarut P, Pathanapitoon K. Vogt-Koyanagi-Harada disease in Thailand. Ocul Immunol Inflamm. 2012;20:419–422. doi:10.3109/09273948.2012.723780.
   PubMed Web of Science ®Google Scholar
• Quek D, Jap A, Chee S. Risk factors for poor visual outcome following cataract surgery in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2011;95:1542–1546. doi:10.1136/bjo.2010.184796.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 2001;131:647–652. doi:10.1016/s0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• AlBloushi AF, Alfawaz AM, Al-Dahmash SA, et al. Incidence, risk factors and surgical outcomes of cataract among patients with uveitis in a University Referral Hospital in Riyadh, Saudi Arabia. Ocul Immunol Inflamm. 2018;24:1–9. doi:10.1080/09273948.2018.1504970.
   Web of Science ®Google Scholar
• Mehta S, Linton MM, Kepen JH. Outcome of cataract surgery in patients with uveitis: a systematic review and meta-analysis. Am J Ophthalmol. 2014;158:676–692. doi:10.1016/j.ajo.2014.06.018.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516. doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum. 2006;55:864–872. doi:10.1002/art.22353.
   PubMed Web of Science ®Google Scholar
• van Nies JA, Krabben A, Schoones JW, Huizinga TWJ, Kloppenburg M, van der Helm-van Mil AHM. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73:861–870. doi:10.1136/annrheumdis-2012-203130.
   PubMed Web of Science ®Google Scholar
• Herbort CP Jr, Abu El-Asrar AM, Takeuchi M, et al. Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease. Int Ophthalmol. 2018 Jun 11. doi:10.1007/s10792-018-0949-4.
   Web of Science ®Google Scholar
• Ji Y, Hu K, Li C, et al. Outcome and prognostic factors of phacoemulsification cataract surgery in Vogt-Koyanagi-Harada uveitis. Am J Ophthalmol. Sep 5, 2018; pii: S0002-9394(18)30502-6. doi:10.1016/j.ajo.2018.08.041.
   Web of Science ®Google Scholar
• Bawazeer A. Phacoemulsification cataract extraction in patient with behçet’s disease. J King Abdulaziz Univ Med Sci. 2010;17:31–40. doi:10.4197/Med.17-4.3.
   Google Scholar
• Elgohary MA, McCluskey PJ, Towler HM, et al. Outcome of phacoemulsification in patients with uveitis. Br J Ophthalmol. 2007;91:916–921. doi:10.1136/bjo.2007.114801.
   PubMed Web of Science ®Google Scholar